ES2167733T3 - Inhibidores de metaloproteinasa matricial de bifenilsulfonamida. - Google Patents
Inhibidores de metaloproteinasa matricial de bifenilsulfonamida.Info
- Publication number
- ES2167733T3 ES2167733T3 ES97918788T ES97918788T ES2167733T3 ES 2167733 T3 ES2167733 T3 ES 2167733T3 ES 97918788 T ES97918788 T ES 97918788T ES 97918788 T ES97918788 T ES 97918788T ES 2167733 T3 ES2167733 T3 ES 2167733T3
- Authority
- ES
- Spain
- Prior art keywords
- bifenylsulfonamide
- alkyl
- matrix metaloproteinase
- metaloproteinase inhibitors
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000011159 matrix material Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000002808 connective tissue Anatomy 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- -1 nitro, amino Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/42—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1746096P | 1996-05-17 | 1996-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2167733T3 true ES2167733T3 (es) | 2002-05-16 |
Family
ID=21782716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97918788T Expired - Lifetime ES2167733T3 (es) | 1996-05-17 | 1997-04-24 | Inhibidores de metaloproteinasa matricial de bifenilsulfonamida. |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0901466B1 (OSRAM) |
| JP (1) | JP2000511175A (OSRAM) |
| KR (1) | KR20000011095A (OSRAM) |
| CN (1) | CN1077885C (OSRAM) |
| AT (1) | ATE207891T1 (OSRAM) |
| BG (1) | BG63940B1 (OSRAM) |
| BR (1) | BR9710841A (OSRAM) |
| CA (1) | CA2253342A1 (OSRAM) |
| CZ (1) | CZ294063B6 (OSRAM) |
| DE (1) | DE69707865T2 (OSRAM) |
| DK (1) | DK0901466T3 (OSRAM) |
| EA (1) | EA001561B1 (OSRAM) |
| EE (1) | EE03965B1 (OSRAM) |
| ES (1) | ES2167733T3 (OSRAM) |
| IL (1) | IL126832A0 (OSRAM) |
| NO (1) | NO312510B1 (OSRAM) |
| NZ (1) | NZ332711A (OSRAM) |
| PL (1) | PL186416B1 (OSRAM) |
| PT (1) | PT901466E (OSRAM) |
| SK (1) | SK282863B6 (OSRAM) |
| WO (1) | WO1997044315A1 (OSRAM) |
| ZA (1) | ZA974223B (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0766665T3 (da) * | 1994-06-22 | 1999-12-06 | British Biotech Pharm | Metalloproteinaseinhibitorer |
| US6124333A (en) * | 1995-06-22 | 2000-09-26 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
| BR9714385A (pt) * | 1996-12-09 | 2000-05-16 | Warner Lambert Co | Método para tratamento e prevenção de deficiência cardìaca e dilatação ventricular |
| EP1366765A1 (en) * | 1996-12-17 | 2003-12-03 | Warner-Lambert Company Llc | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing |
| PT946166E (pt) | 1996-12-17 | 2004-06-30 | Warner Lambert Co | Utilizacao de inibidores das metaloproteinases da matriz para tratar disturbios neurologicos e promover a cicatrizacao de feridas |
| GB9706255D0 (en) * | 1997-03-26 | 1997-05-14 | Smithkline Beecham Plc | Novel compounds |
| DE19719621A1 (de) * | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
| DE69836877D1 (de) * | 1997-07-22 | 2007-02-22 | Shionogi & Co | Verwendung von Matrix- Metalloproteinase Inhibitoren zur Behandlung oder Vorbeugung von Glomerulopathie |
| ES2184340T3 (es) * | 1997-12-23 | 2003-04-01 | Warner Lambert Co | Combinaciones de inhibidores de la enzima de conversion de la angiotensina e inhibidores de la enzima metaloproteinasa matricial. |
| US6410580B1 (en) | 1998-02-04 | 2002-06-25 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
| KR20010040698A (ko) * | 1998-02-04 | 2001-05-15 | 한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터 | 기질 분해 메탈로프로테이나제를 억제하는 술포닐아미노유도체 |
| AU1591699A (en) * | 1998-03-17 | 1999-10-11 | Warner-Lambert Company | Statin-matrix metalloproteinase inhibitor combinations |
| EP0967201A1 (en) * | 1998-05-20 | 1999-12-29 | Roche Diagnostics GmbH | Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors |
| PL199234B1 (pl) * | 1998-07-16 | 2008-08-29 | Sanofi Aventis Deutschland | Pochodne kwasu fosfinowego i kwasu fosfonowego, związki pośrednie, sposób wytwarzania tych pochodnych, środek leczniczy, zastosowanie tych pochodnych i sposób wytwarzania środka leczniczego |
| HUP0102880A3 (en) * | 1998-07-21 | 2002-11-28 | Warner Lambert Co | Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions |
| DE19851184A1 (de) | 1998-11-06 | 2000-05-11 | Aventis Pharma Gmbh | N-Arylsulfonyl-aminosäure-omega-amide |
| US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US6495578B1 (en) * | 1999-04-19 | 2002-12-17 | Shionogi & Co., Ltd. | Sulfonamide derivatives having oxadiazole rings |
| GB9918684D0 (en) | 1999-08-09 | 1999-10-13 | Novartis Ag | Organic compounds |
| MXPA02004985A (es) | 1999-11-26 | 2003-10-14 | Shionogi & Co | Antagonistas del neuropeptido y, y5. |
| US6949566B2 (en) * | 2000-09-29 | 2005-09-27 | Shionogi & Co. Ltd. | Thiazole and oxazole derivatives |
| GB0103303D0 (en) | 2001-02-09 | 2001-03-28 | Novartis Ag | Organic compounds |
| MXPA01013326A (es) * | 2001-02-14 | 2002-08-26 | Warner Lambert Co | Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz. |
| WO2003035610A1 (en) * | 2001-10-26 | 2003-05-01 | Shionogi & Co., Ltd. | Sulfonamide derivative having mmp inhibitory activity |
| GB0314488D0 (en) * | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Therapeutically useful compounds |
| JP2007525406A (ja) * | 2003-12-04 | 2007-09-06 | ワイス | ビアリールスルホンアミドおよびその使用方法 |
| KR20070046025A (ko) | 2004-03-22 | 2007-05-02 | 써던 리서취 인스티튜트 | 매트릭스 메탈로프로테이나제의 비펩티드 억제제 |
| CN101279956B (zh) * | 2008-04-25 | 2011-06-15 | 南昌大学 | 一种基质金属蛋白酶抑制剂及合成方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
| DK0766665T3 (da) * | 1994-06-22 | 1999-12-06 | British Biotech Pharm | Metalloproteinaseinhibitorer |
-
1997
- 1997-04-24 DE DE69707865T patent/DE69707865T2/de not_active Expired - Fee Related
- 1997-04-24 CN CN97194719A patent/CN1077885C/zh not_active Expired - Fee Related
- 1997-04-24 EE EE9800397A patent/EE03965B1/xx not_active IP Right Cessation
- 1997-04-24 PT PT97918788T patent/PT901466E/pt unknown
- 1997-04-24 KR KR1019980709253A patent/KR20000011095A/ko not_active Ceased
- 1997-04-24 EA EA199800988A patent/EA001561B1/ru not_active IP Right Cessation
- 1997-04-24 DK DK97918788T patent/DK0901466T3/da active
- 1997-04-24 ES ES97918788T patent/ES2167733T3/es not_active Expired - Lifetime
- 1997-04-24 CA CA002253342A patent/CA2253342A1/en not_active Abandoned
- 1997-04-24 AT AT97918788T patent/ATE207891T1/de not_active IP Right Cessation
- 1997-04-24 EP EP97918788A patent/EP0901466B1/en not_active Expired - Lifetime
- 1997-04-24 IL IL12683297A patent/IL126832A0/xx unknown
- 1997-04-24 BR BR9710841A patent/BR9710841A/pt not_active IP Right Cessation
- 1997-04-24 WO PCT/US1997/006801 patent/WO1997044315A1/en not_active Ceased
- 1997-04-24 JP JP09542377A patent/JP2000511175A/ja not_active Abandoned
- 1997-04-24 NZ NZ332711A patent/NZ332711A/en unknown
- 1997-04-24 CZ CZ19983668A patent/CZ294063B6/cs not_active IP Right Cessation
- 1997-04-24 SK SK1577-98A patent/SK282863B6/sk unknown
- 1997-04-24 PL PL97329929A patent/PL186416B1/pl not_active IP Right Cessation
- 1997-05-15 ZA ZA9704223A patent/ZA974223B/xx unknown
-
1998
- 1998-11-12 BG BG102918A patent/BG63940B1/bg unknown
- 1998-11-16 NO NO19985326A patent/NO312510B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EA001561B1 (ru) | 2001-04-23 |
| KR20000011095A (ko) | 2000-02-25 |
| DE69707865T2 (de) | 2002-05-02 |
| CN1219166A (zh) | 1999-06-09 |
| EP0901466B1 (en) | 2001-10-31 |
| EP0901466A1 (en) | 1999-03-17 |
| DK0901466T3 (da) | 2002-02-18 |
| EE9800397A (et) | 1999-06-15 |
| AU713286B2 (en) | 1999-11-25 |
| CN1077885C (zh) | 2002-01-16 |
| NZ332711A (en) | 2000-06-23 |
| SK282863B6 (sk) | 2002-12-03 |
| JP2000511175A (ja) | 2000-08-29 |
| EA199800988A1 (ru) | 1999-04-29 |
| PL186416B1 (pl) | 2004-01-30 |
| SK157798A3 (en) | 1999-04-13 |
| AU2680397A (en) | 1997-12-09 |
| IL126832A0 (en) | 1999-08-17 |
| NO985326L (no) | 1999-01-14 |
| CZ366898A3 (cs) | 1999-02-17 |
| ZA974223B (en) | 1997-12-10 |
| CZ294063B6 (cs) | 2004-09-15 |
| PL329929A1 (en) | 1999-04-26 |
| BR9710841A (pt) | 1999-08-17 |
| BG102918A (en) | 1999-09-30 |
| NO985326D0 (no) | 1998-11-16 |
| ATE207891T1 (de) | 2001-11-15 |
| WO1997044315A1 (en) | 1997-11-27 |
| HK1019585A1 (en) | 2000-02-18 |
| DE69707865D1 (de) | 2001-12-06 |
| NO312510B1 (no) | 2002-05-21 |
| EE03965B1 (et) | 2003-02-17 |
| PT901466E (pt) | 2002-04-29 |
| BG63940B1 (bg) | 2003-07-31 |
| CA2253342A1 (en) | 1997-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2167733T3 (es) | Inhibidores de metaloproteinasa matricial de bifenilsulfonamida. | |
| AU6894800A (en) | Caspase inhibitors and uses thereof | |
| ID21526A (id) | 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus | |
| WO2003024448A3 (en) | Inhibitors of histone deacetylase | |
| NO996269L (no) | Kinolin-indol antimikrobielle midler, samt anvendelse og blandinger derav | |
| ATE289590T1 (de) | Beta-sulfonyl-hydroxamsäuren als matrix- metalloproteinaseinhibitoren | |
| NZ332762A (en) | Isobutylgaba and its derivatives for the treatment of pain | |
| PL343495A1 (en) | Heterocyclically substituted amides used as calpain inhibitors | |
| BR9805544A (pt) | Uso de um composto. | |
| DE69811111D1 (de) | Hydroxamsäure- und carbonsäurederivate mit mmp und tnf hemmender wirkung | |
| EA200100804A1 (ru) | Сульфоароматические производные гидроксамовой кислоты как ингибиторы металлопротеаз | |
| DK0946166T3 (da) | Anvendelse af matrixmetalloproteinaseinhibitorer til fremme af sårheling | |
| NZ333550A (en) | Matrix metalloproteinase inhibitors for inhibiting the release of TNF | |
| CA2266759A1 (en) | 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase | |
| AU1314300A (en) | Methods and compositions for inhibiting polymerization of ethylenically unsaturated hydrocarbons | |
| AU2001255646A1 (en) | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives | |
| CO4900041A1 (es) | Inhibidores de metaloproteinasa de matriz de acido butirico enzimas metaloproteinasa de matriz y metodo de tratamiento con los mismos | |
| WO2004048368A3 (en) | Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors | |
| ES2173634T3 (es) | Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf. | |
| PT971714E (pt) | Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia | |
| NO20075410L (no) | Vetrinaerbruk av et pleuromutilinderivat |